talijanski

Effetti di BRMs sulle proprieta antitumorali di ciclofosfamide, cisplatino, 5-FU e dacarbazina in tumori solidi avanzati

A new biological response modifier, L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine hydrochloride (AdTP, recently synthesized and characterized for antitumor, antiviral and immunomodulating properties, was studied in comparison to the peptidoglycan monomer (PGM) isolated from Brevibacterium divaricatum to test the effects of their use concomitant to that of anticancer cytotoxic drugs such as cyclophosphamide, 5-FU, cisplatin and dacarbazine. The experiments performed using Lewis lung carcinoma and MCa mammary carcinoma in CBA mice, indicated that AdTP and PGM increased some immunological parameters of lymphocytes isolated from the spleens of treated mice. AdTP increased the effect of 5-FU on lung metastases but failed to show any increase in life expectancy with the treatment performed

Adamantil-derivato; peptidoglicano; Lewis lung carcinoma; ciclofosfamide; cisplatino; 5-FU; dacarbazina

nije evidentirano